OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 551 - 560 of 797 studies

Cancer and neoplasms

A Phase III, Randomized, Open Label, Multicenter Study Evaluating The Efficacy And Safety Of Cevostamab In Combination With Pomalidomide And Dexamethasone Versus Standard Of Care In Patients With Multiple Myeloma Who Have Received One To Three Prior Lines Of Therapy (CEVOLUTION)

Cancer and neoplasms

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma (M25-275)

Cancer and neoplasms

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Patients with Newly-Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Neurological

Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-304)

Eye

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Male Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE) (ATSN-201-1 (LIGHTHOUSE))

Blood Cancer and neoplasms

Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions (ELRISE MDS)

Stroke

NeVa One Registry - Prospective, Open-Label, Multi-Center Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes (NeVa One)

Stroke

A multicenter, double-blinded, placebo-controlled, single ascending dose, two-part, randomized, phase 2 clinical trial to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BB-031 in acute ischemic stroke (AIS) patients (RAISE)

Neurological

A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG) (THYME)

Exploring the lived experience of patients with Congenital Myasthenic Syndromes (CMS) about assessment tools used clinically and patient view on what might capture meaningful change.